Literature DB >> 12419319

Shedding of the luminal domain of the neurotensin receptor-3/sortilin in the HT29 cell line.

Valérie Navarro1, Jean-Pierre Vincent, Jean Mazella.   

Abstract

The neurotensin (NT) receptor-3/sortilin (NTR3) belongs to the new receptor family of VPS10P domain containing receptors. The NTR3 is expressed in all cancer cells on which NT activates cell growth and its cellular location is mainly intracellular within the endoplasmic reticulum and the trans-Golgi network. However, the NTR3 is also present at the cell surface of the HT29 cell line from which it is released by a mechanism activated by phorbol 12-myristate 13-acetate (PMA). The shedding of the NTR3 is sensitive to protein kinase C (PKC) and mitogen-activated protein (MAP) kinase inhibitors and to 1,10-phenanthroline and BB3103, suggesting the activation of zinc-metalloproteases and the ADAM10 (a desintegrin and metalloprotease). The shedding of the membrane NTR3 leads to a soluble protein able to bind exogenous NT, suggesting a role of this process in the biological activity of the peptide.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12419319     DOI: 10.1016/s0006-291x(02)02564-0

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  29 in total

1.  Tumour necrosis factor alpha-converting enzyme mediates ectodomain shedding of Vps10p-domain receptor family members.

Authors:  Guido Hermey; Susanne S Sjøgaard; Claus Munck Petersen; Anders Nykjaer; Jørgen Gliemann
Journal:  Biochem J       Date:  2006-04-15       Impact factor: 3.857

Review 2.  The Vps10p-domain receptor family.

Authors:  Guido Hermey
Journal:  Cell Mol Life Sci       Date:  2009-05-12       Impact factor: 9.261

Review 3.  Targeting two-pore domain K(+) channels TREK-1 and TASK-3 for the treatment of depression: a new therapeutic concept.

Authors:  M Borsotto; J Veyssiere; H Moha Ou Maati; C Devader; J Mazella; C Heurteaux
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

4.  Neuronal brain-derived neurotrophic factor is synthesized in excess, with levels regulated by sortilin-mediated trafficking and lysosomal degradation.

Authors:  Sarah Felice Evans; Krithi Irmady; Katya Ostrow; Taeho Kim; Anders Nykjaer; Paul Saftig; Carl Blobel; Barbara L Hempstead
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

5.  ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin.

Authors:  Henry K Teng; Kenneth K Teng; Ramee Lee; Saundrene Wright; Seema Tevar; Ramiro D Almeida; Pouneh Kermani; Risa Torkin; Zhe-Yu Chen; Francis S Lee; Rosemary T Kraemer; Anders Nykjaer; Barbara L Hempstead
Journal:  J Neurosci       Date:  2005-06-01       Impact factor: 6.167

6.  Palmitate-induced down-regulation of sortilin and impaired GLUT4 trafficking in C2C12 myotubes.

Authors:  Yo Tsuchiya; Hiroyasu Hatakeyama; Natsumi Emoto; Fumie Wagatsuma; Shinichi Matsushita; Makoto Kanzaki
Journal:  J Biol Chem       Date:  2010-08-30       Impact factor: 5.157

7.  Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism.

Authors:  Arti B Patel; Irene Tsilioni; Susan E Leeman; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-23       Impact factor: 11.205

Review 8.  Multi-tasking by the p75 neurotrophin receptor: sortilin things out?

Authors:  Francisca C Bronfman; Mike Fainzilber
Journal:  EMBO Rep       Date:  2004-09       Impact factor: 8.807

Review 9.  Trafficking in Alzheimer's Disease: Modulation of APP Transport and Processing by the Transmembrane Proteins LRP1, SorLA, SorCS1c, Sortilin, and Calsyntenin.

Authors:  Simone Eggert; Carolin Thomas; Stefan Kins; Guido Hermey
Journal:  Mol Neurobiol       Date:  2017-10-27       Impact factor: 5.590

Review 10.  Sortilin and Its Multiple Roles in Cardiovascular and Metabolic Diseases.

Authors:  Claudia Goettsch; Mads Kjolby; Elena Aikawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-30       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.